The deficit is a measurement-system failure
Women’s health is often framed as a representation problem: recruit more women and the evidence gap will close. Representation is necessary, but the diagnosis is incomplete. A useful evidence system must decide which biological variables, exposures, symptoms, treatments, social conditions, and outcomes to measure; preserve their timing; and retain enough context to compare subgroups without collapsing them into an average. A larger dataset built from episodic visits can still miss cyclical, pregnancy-related, perimenopausal, or treatment-linked changes. The engineering object is therefore a longitudinal measurement system, not a demographic field added to an existing database.
The scale of unresolved need is visible in conditions that have high prevalence but weak diagnostic pathways. WHO estimates that endometriosis affects about 190 million reproductive-age women and girls worldwide. A recent systematic review found that reported delays remain heterogeneous: contemporary estimates can be shorter in some settings, while earlier studies reported five-to-thirteen-year intervals from first symptoms to diagnosis. Those figures cannot be combined into one universal delay, but they demonstrate why timestamps, referral steps, prior negative tests, symptom trajectories, and access barriers belong in the research record.
Enrollment parity does not guarantee analytical parity
The 1993 NIH Revitalization Act established inclusion requirements for women and minority groups in NIH-funded clinical research, and NIH now publishes enrollment information by research category. That policy changed the formal baseline. It did not ensure that every study is powered to examine treatment-effect heterogeneity, reports results by sex, or captures gendered exposures and care pathways. Aggregate participation can also conceal condition-level gaps: a portfolio may enroll many women in high-volume studies while leaving specific disorders, life stages, or underserved populations thinly measured. A serious audit asks whether the scientific question, sampling frame, endpoint, and analysis plan can answer the subgroup question being claimed.
Sex and gender must also be handled with precision rather than interchangeably. Sex-related variables can include chromosomes, hormones, anatomy, pregnancy status, body composition, and metabolism. Gender-related variables can include occupation, caregiving, income, violence exposure, health-seeking behavior, and clinician response. Not every study needs every variable, but each should state its causal model and measurement rationale. Otherwise a model may use sex as a convenient proxy for unmeasured mechanisms, producing correlations that travel poorly across populations and obscure actionable causes.
Medication evidence shows why stratified analysis matters
A review of 86 drugs with published sex-specific pharmacokinetic evidence found higher exposure in women for 76 drugs. Among 59 drugs with both pharmacokinetic and adverse-reaction evidence, the direction of the pharmacokinetic difference agreed with the adverse-reaction bias in 52 cases. For drugs with higher pharmacokinetic values in women, 96% were associated with more adverse reactions in women. These are descriptive findings from a selected evidence base, not a rule for individual dosing, but they demonstrate that equal administered dose does not necessarily produce equal exposure.
The systems implication is concrete. Trials and post-market surveillance should preserve dose, formulation, adherence, body size, renal and hepatic function, concomitant medication, hormonal state where relevant, exposure estimates, and adverse-event timing. Analysis should report denominators and uncertainty, distinguish spontaneous reports from adjudicated events, and avoid treating a group average as an individual prescription. A digital platform cannot infer a clinically valid dose adjustment merely from population correlations. It can, however, make the evidence chain inspectable and identify where a prospectively governed study is warranted.
Longitudinal records need event meaning, not just chronology
A continuous record becomes scientifically useful when observations retain provenance and clinical meaning. A symptom entry should record instrument, scale, language, context, and missingness. A laboratory result needs specimen time, reference range, assay method, and unit. A wearable stream needs device and firmware versions, wear time, quality flags, and the transformation from raw signal to derived measure. Treatments require indication, dose, start and stop dates, response, and reason for discontinuation. Without these fields, an apparently rich timeline can support attractive visualization while remaining unsuitable for causal or clinical inference.
Consent must be equally longitudinal. Permission for direct care is not permission for research, model training, commercial reuse, or cross-border transfer. A robust design makes purpose, recipient, data class, duration, revocation, and emergency exceptions explicit and machine-readable where law and standards permit. It also records policy versions and every consequential access. The objective is not to place an immutable copy of intimate data on a public ledger; it is to make authorization and use accountable while retaining lawful correction, deletion, and withdrawal pathways.
Maternal mortality makes the deployment boundary visible
The UN inter-agency estimate of about 260,000 maternal deaths in 2023 is a population-level signal of unequal access, quality, and continuity. The global maternal mortality ratio fell by about 40% between 2000 and 2023, yet progress remains far from the Sustainable Development Goal threshold of fewer than 70 deaths per 100,000 live births by 2030. A data product cannot substitute for emergency obstetric capacity, trained staff, transport, blood supply, or accountable referral. Its valid role is narrower: reveal delays, maintain a risk-aware handoff, support surveillance, and test whether interventions change defined process and outcome measures.
That distinction should shape evaluation. A deployment study should pre-specify the care decision the system supports, the professional responsible, the response window, failure and escalation modes, and the counterfactual pathway without the tool. Process gains such as a completed referral matter, but they should not be relabeled as reduced mortality without an adequately designed study. Safety endpoints should include missed escalation, alarm burden, differential performance, privacy incidents, and care displaced by false reassurance.
A research programme with falsifiable gates
An evidence-led programme begins with a condition and decision, not with an omnibus women’s-health model. Gate one is measurement validity: can the variables be collected reliably across relevant devices, languages, sites, and life stages? Gate two is observational validity: are associations stable under temporal and external evaluation, with missingness and confounding examined? Gate three is clinical utility: does using the system improve a pre-specified decision or outcome compared with current practice? Gate four is operational equity: do access, performance, workload, and benefit remain acceptable across subgroups and settings after deployment?
Every gate needs a registered protocol, versioned data dictionary, analysis plan, uncertainty intervals, error analysis, and a stop or redesign criterion. Negative findings should remain visible because they prevent repeated failure. Evidence maturity should be labeled at the claim level: descriptive, retrospectively validated, prospectively evaluated, or outcome-tested. This architecture will produce fewer sweeping claims, but each surviving claim will be more useful. The goal is not to declare the gap closed; it is to create a system in which the next uncertainty is measurable and the next decision is accountable.
Scope and limitations
The cited figures describe different populations, periods, and evidence types and should not be pooled into a single measure of the women’s-health gap. WHO prevalence and mortality values are modeled global estimates. The pharmacokinetic review covers drugs for which sex-specific evidence was available and does not authorize individual dose changes. Diagnostic-delay studies use heterogeneous definitions and health systems. This article proposes an evidence architecture, not medical advice, a clinical protocol, or proof that any named platform improves outcomes.
References
Source review: 20 August 2026. Quantitative values retain their original definitions, periods, and boundaries.
- 01Endometriosis
World Health Organization · 2025
www.who.int ↗ - 02Trends in maternal mortality 2000 to 2023
WHO, UNICEF, UNFPA, World Bank Group and UN DESA · 2025
www.who.int ↗ - 03Inclusion of Women and Minorities in Clinical Research
US National Institutes of Health · 2025
report.nih.gov ↗ - 04A New Vision for Women’s Health Research
National Academies of Sciences, Engineering, and Medicine · 2024
www.ncbi.nlm.nih.gov ↗ - 05Sex differences in pharmacokinetics predict adverse drug reactions in women
Biology of Sex Differences · 2020
pmc.ncbi.nlm.nih.gov ↗ - 06Time to Diagnose Endometriosis: Current Status, Challenges and Regional Characteristics
BJOG · 2024
pmc.ncbi.nlm.nih.gov ↗